Antithrombin III (Human, Grifols)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAntithrombin III (Human, Grifols)
Drug Alias Name抗凝血酶III (Grifols)Thrombate III
ClassificationBiologics > Protein drugs > Enzyme > Non-recombinant enzyme
Mechanisms of ActionCoagulation factor X inhibitorsThrombin inhibitorsAntithrombin-III replacements
TargetsProthrombinCoagulation factor X
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Wounds and InjuriesPostoperative Complications +[9] 
Global Approved IndicationsAntithrombin III DeficiencyThromboembolism
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1991/12/30
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGrifols Sa
China Registration ClassN/A

Develop Information

Active CompaniesGrifols Shared Services North America IncEndpoint Health IncGrifols Biologicals Llc
Inactive CompaniesGrifols Therapeutics Llc
Active IndicationsWounds and InjuriesAntithrombin III DeficiencyVenous Thromboembolism +[4] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Postoperative ComplicationsVenous Thrombosis +[5] 

Other Information

ATC CodeB01AB02
Related LinksN/A